Pretreatment CT-based machine learning radiomics model to predict response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy.

被引：0
|
作者：
Shang, Changzhen [1 ]
Hua, Yonglin [1 ]
Chen, Yajin [1 ]
Zhuang, Hongkai [1 ]
机构：
[1] Sun Yat sen Univ, Sun Yat sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 23_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.23_suppl.94
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：94 / 94
页数：1
相关论文
共 50 条
  • [1] Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
    Wu, Xuewei
    You, Jingjing
    Zhang, Shuixing
    Zhang, Bin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (09)
  • [2] Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
    Hua, Yonglin
    Sun, Zhixian
    Xiao, Yuxin
    Li, Huilong
    Ma, Xiaowu
    Luo, Xuan
    Tan, Wenliang
    Xie, Zhiqin
    Zhang, Ziyu
    Tang, Chenwei
    Zhuang, Hongkai
    Xu, Weikai
    Zhu, Haihong
    Chen, Yajin
    Shang, Changzhen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07) : 1 - 15
  • [3] MACHINE LEARNING RADIOMICS BASED ON CT TO PREDICT RESPONSE TO LENVATINIB PLUS PD-1 INHIBITOR FOR HEPATOCELLULAR CARCINOMA
    Bo, Zhiyuan
    Zhao, Zhengxiao
    Xie, Xiaozai
    Wang, Yi
    Bo, Zhiyuan
    HEPATOLOGY, 2024, 80
  • [4] Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
    Zhao, Shu
    Zhou, Minhang
    Wang, Peng
    Yang, Jing
    Zhang, Dong
    Yin, Fan
    Song, Peng
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2022, 21
  • [5] Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
    Wang, Jinfeng
    Zhao, Man
    Han, Guangjie
    Han, Xin
    Shi, Jianfei
    Mi, Lili
    Li, Ning
    Yin, Xiaolei
    Duan, Xiaoling
    Hou, Jiaojiao
    Yin, Fei
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [6] Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
    Wang, Jinfeng
    Zhao, Man
    Han, Guangjie
    Han, Xin
    Shi, Jianfei
    Mi, Lili
    Li, Ning
    Yin, Xiaolei
    Duan, Xiaoling
    Hou, Jiaojiao
    Yin, Fei
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [7] Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
    Li, Xingzhi
    Chen, Jie
    Wang, Xiaobo
    Bai, Tao
    Lu, Shaolong
    Wei, Tao
    Tang, Zhihong
    Huang, Chengwen
    Zhang, Bin
    Liu, Bowen
    Li, Lequn
    Wu, Feixiang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [8] The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study
    Ding, Zongren
    Fang, Guoxu
    Tang, Yanyan
    Zeng, Yongyi
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [9] Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors
    Yin, Linan
    Liu, Ruibao
    Li, Wei
    Li, Shijie
    Hou, Xunbo
    BMC GASTROENTEROLOGY, 2025, 25 (01)
  • [10] Peripheral Th and NK cells are associated with response to lenvatinib plus PD-1 inhibitor in unresectable hepatocellular carcinoma
    Zou, Yiping
    Chen, Zhihong
    Chen, Zhenrong
    Zhang, Yuanpeng
    Zheng, Zehao
    Wu, Fan
    Xu, Lianqun
    Li, Qiao
    Lin, Ye
    Shi, Ning
    Jin, Haosheng
    CLINICAL IMMUNOLOGY, 2023, 249
12345